“…7 In patients with multiple risk factors for HF, CMR has the potential to differentiate anthracycline-induced cardiomyopathy from other non-ischemic causes of HF, such as AF, and may play an essential role in guiding HF management and improving patient outcomes. 8,9 Recent studies have explored the prognostic value of CMR in predicting LVEF improvement following AF ablation in patients with non-ischemic heart failure with reduced ejection fraction (HFrEF). 5,10 The absence of LV fibrosis, as detected by LGE and T1 extracellular volume fraction mapping, has been shown to correlate with greater improvement in LV systolic function following AF ablation.…”